Fiche société
Alzheon Inc.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Experimental: ALZ-801This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo. | Alzheimer | Phase 3 | À vérifier | United States, Canada, Czechia, France, Germany, Iceland, Netherlands, Spain, … | À vérifier |
| Experimental: ALZ-801This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo. | Alzheimer | Phase 3 | À vérifier | United States, Canada, Czechia, France, Germany, Iceland, Netherlands, Spain, United Kingdom | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Experimental: ALZ-801 | Alzheimer | Phase 3 | NCT04770220 | APOLLOE4 — An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects | COMPLETED |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Experimental: ALZ-801 | ALZ-801 prevents amyloid β-protein assembly and reduces cytotoxicity: A preclinical experimental study. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | ||
| Experimental: ALZ-801 | Naringenin as a dual-target modulator of RAGE-NF-κB signaling and Aβ fibrillization in Alzheimer's disease: integrated computational and experimental analyses. | Frontiers in pharmacology |